# Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

> **NCT06323655** · PHASE1 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Tasimelteon
- **DRUG:** Active Control Placebo
- **DRUG:** Tasimelteon Placebo
- **DRUG:** Active Control

## Key facts

- **NCT ID:** NCT06323655
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-19
- **Primary completion:** 2018-08-28
- **Final completion:** 2018-08-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06323655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06323655, "Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06323655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*